AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in healthy late preterm and term infants. RSV infections cause about 80,000 hospitalizations in children and 500 deaths each year.
Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator.
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants), which was cleared for Phase I trials, employs codon deoptimization to evoke a stronger-than-usual immune response.
Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.
Researchers at Weill Cornell Medicine identified a specific and unique kind of immune cell activity in the lungs of Covid-19 patients that is different from the type of immune cell activity found in other respiratory infections.
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.
An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.
Enanta Pharmaceuticals Inc.’s treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study.